Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2022-02-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the actual controlling shareholders of the company. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, the purpose of the pledge, and assurances about the financial status and control implications. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about share pledging activity, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2022-02-22 Chinese
关于拟收购股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a proposed acquisition of equity and related party transaction by 瑞康医药集团股份有限公司. It includes extensive information about the transaction, parties involved, shareholding changes, financial data of the target company, valuation reports, and approvals by the board and independent directors. The document is not a full financial report but a specific transaction announcement related to capital acquisition and related party dealings. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is clearly an announcement about a capital transaction and acquisition activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6683 characters) and content support this classification with high confidence.
2022-02-17 Chinese
瑞康医药集团股份有限公司拟股权收购涉及的天津国慧大健康科技有限公司股东全部权益价值项目资产评估报告
Regulatory Filings
2022-02-17 Chinese
瑞康医药独立董事关于第四届董事会第十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an opinion statement from independent directors regarding a specific board meeting agenda item related to an acquisition and related party transaction. It references compliance with stock exchange listing rules and internal governance procedures. The document is short (722 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a formal pre-approval opinion related to board matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions involving the board or senior management. It is not an Annual Report, Audit Report, or any other financial report type. Therefore, the classification is MANG with high confidence.
2022-02-17 Chinese
天津国慧大健康科技有限公司审计报告
Regulatory Filings
2022-02-17 Chinese
瑞康医药独立董事关于第四届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting matter related to an equity acquisition and related party transaction. It references compliance with stock exchange listing rules and corporate governance guidelines. The content is focused on board-level approval and fairness of a transaction, not a full financial report or earnings release. The document length is short (824 characters) and it is a formal opinion rather than a report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board decisions and management oversight on a transaction.
2022-02-17 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.